You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the ALBUMIN HUMAN Drug Excipient Business Development Opportunity Report, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ALBUMIN HUMAN


✉ Email this page to a colleague

« Back to Dashboard


Biosimilar Clinical Trials for albumin human

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT04670978 ↗ Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer Recruiting Shandong University Phase 2 2021-03-31 The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel) and bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian cancer, fallopian tube cancer or peritoneal carcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for albumin human

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000117 ↗ Intravenous Immunoglobulin Therapy in Optic Neuritis Completed National Eye Institute (NEI) Phase 3 1995-08-01 To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).
NCT00000580 ↗ Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1975-11-01 To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.
NCT00000582 ↗ Cooperative Study of Factor VIII Inhibitors Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1978-07-01 To test the efficacy of prothrombin complex concentrates (Factor IX) in the treatment of hemophiliac patients who had inhibitors to Factor VIII.
NCT00000720 ↗ A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1969-12-31 To evaluate the clinical, immunologic, and virologic effects of oral zidovudine (AZT) plus intravenous immunoglobulin (IVIG) versus AZT plus placebo (albumin). It is estimated that by 1991, there may be 10,000 to 20,000 HIV-infected children in the United States. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in changing the course of disease and decreasing mortality in this vulnerable population. AZT treatment has been shown to decrease mortality and the frequency of opportunistic infections in certain adult AIDS patients; therefore, it is likely that children may also benefit from this antiviral therapy. In addition, bacterial infections are frequently found in HIV-infected children. Because pooled human serum immunoglobulin, another name for antibodies, is effective in reducing bacterial infection in patients with defects of immunity, it may reduce the rate of bacterial infection in HIV-infected children as well. In this study, AZT will be administered together with IVIG to determine safety, tolerance, and efficacy of the combined treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for albumin human

Condition Name

Condition Name for albumin human
Intervention Trials
Breast Cancer 45
Diabetic Nephropathy 38
Diabetes Mellitus, Type 2 28
Hypertension 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for albumin human
Intervention Trials
Kidney Diseases 117
Breast Neoplasms 94
Diabetes Mellitus 89
Diabetes Mellitus, Type 2 85
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for albumin human

Trials by Country

Trials by Country for albumin human
Location Trials
China 290
Canada 155
Italy 95
Spain 87
Australia 80
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for albumin human
Location Trials
California 103
New York 91
Texas 80
Illinois 78
Maryland 65
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for albumin human

Clinical Trial Phase

Clinical Trial Phase for albumin human
Clinical Trial Phase Trials
Phase 4 270
Phase 3 175
Phase 2/Phase 3 45
[disabled in preview] 410
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for albumin human
Clinical Trial Phase Trials
Completed 558
Recruiting 228
Unknown status 166
[disabled in preview] 161
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for albumin human

Sponsor Name

Sponsor Name for albumin human
Sponsor Trials
National Cancer Institute (NCI) 68
Celgene Corporation 32
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 23
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for albumin human
Sponsor Trials
Other 1717
Industry 485
NIH 137
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.